Abstract

Objective To detect the promoter methylation status of O6-methylguanine-DNA-methyhransferase(MGMT) gene in the serum of non-small cell lung cancer(NSCLC) patients and to discuss its clinical significance.Methods Serum DNA was extracted from 62 patients with NSCLC,30 patients with benign pulmonary disease and 16 health subjects with medical check-up.The methylation status of MGMT gene was detected by bisulfite genomic sequence and the correlation of methylation profiles with clinical characteristics was analyzed.Results Aberrant promoter methylation of MGMT was detected in 17 of 62 (27.42%) NSCLC patients,but in none of patients with benign pulmonary disease and health subjects with medical check-up(Fisher exact test,P＜0.01).The promoter hypermethylation of MGMT correlated with late stage(P＜0.05),but not with age,gender,histopathology or differentiation in NSCLC patients,The smoking index in methylated patients was higher than that in unmethylated patients(P＜0.01).Conclusions The promoter hypermethylation of MGMT may play an important role in the tumorigenesis and progression,and it is hopeful to become a biomarker for auxiliary diagnosis in NSCLC. Key words: Lung neoplasms/non-small-cell; O6-methylguanine-DNA-methyltransferase; DNA Methylation; DNA Sequence Analysis; Serum

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.